The normal prostate and early-stage prostate cancers depend on androgens for growth and
survival, and androgen ablation therapy causes them to regress. Cancers that are not cured …

Prostate cancers that are progressing on medical and surgical therapies designed to ablate
the action of androgens continue to express androgen receptor (AR) and to depend on …

BACKGROUND The majority of the prostatic cancers are adenocarcinomas characterized by
glandular formation and the expression of luminal differentiation markers androgen receptor …

Prostate cancer afflicts one man in nine over the age of 65 and represents the most
frequently diagnosed cancer in American men (Coffey 1993). Early detection through serum …

Molecular profiling of cancer at the transcript level has become routine. Large-scale analysis
of proteomic alterations during cancer progression has been a more daunting task. Here, we …

Purpose: The transforming growth factor α-epidermal growth factor receptor (EGFR)
autocrine pathway has been implicated in prostate cancer cell growth. Amplification and/or …

This study examined androgen receptor (AR) gene amplification and protein expression in
102 matched paired hormone sensitive and resistant tumours from 51 patients. AR gene …

The androgen receptor (AR) is involved in the development and progression of prostate
cancer. In order to find new compounds that may present novel mechanisms to attenuate the …

BACKGROUND Wnt‐1 and β‐catenin expression levels play an important role in several
malignancies. The authors determined the level of production of Wnt‐1 and β‐catenin in …

Background: Human prostate cancers are initially androgen dependent but ultimately
become androgen independent. Overexpression of the Her-2-neu receptor tyrosine kinase …